Drugs / ASB17061
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01756898 | Nov 2012 → Jan 2014 | atopic eczema | Daiichi Sankyo | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASB17061 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01756898 ↗ |
| Route | Oral | “Oral administration of 5 mg ASB17061 taken once daily for 28 consecutive days.” NCT01756898 ↗ |